- In October 2023, Moderna Inc. revealed the results of its mRNA-based vaccine targeting both influenza and COVID-19, showcasing its potential for combined respiratory disease prevention
- In May 2023, GSK, in partnership with CureVac, launched a Phase I/II clinical trial for their mRNA-based influenza vaccine, marking a significant step in advancing innovative vaccine solutions
- In September 2022, Pfizer Inc. began a Phase 3 clinical trial for its mRNA-based influenza vaccine, enrolling 25,000 U.S. adults to assess safety, efficacy, immunogenicity, and tolerability of its quadrivalent modified RNA flu vaccine
- In March 2022, Seqirus received Health Canada approval for Flucelvax quadrivalent, a cell-based influenza vaccine for individuals aged two and older, extending eligibility to children aged 2 to 18 years
- In September 2021, Sanofi acquired Translate Bio, a clinical-stage mRNA therapeutics company, to accelerate the development of novel vaccines for influenza and other seasonal diseases
